SEARCH

SEARCH BY CITATION

References

  • Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366375.
  • Alger B. E. (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Progr. Neurobiol. 68, 247286.
  • Anderson W. W. and Collingridge G. L. (2001) The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci. Methods 108, 7183.
  • Andersson M., Usiello A., Borgkvist A. et al. (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 25, 84328438.
  • Bastia E., Xu Y. H., Scibelli A. C., Day Y. J., Linden J., Chen J. F. and Schwarzschild M. A. (2005) A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30, 891900.
  • Brewer G. J., Torricelli J. R., Evege E. K. and Price P. J. (1993) Optimized survival of Hippocampal Neurons in B27-supplemented neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35, 567576.
  • Calabresi P., Centonze D., Pisani A. and Bernatrdi G. (1997) Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J. Neurosci. 17, 45094516.
  • Carriba P., Ortiz O., Patkar K. et al. (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 22492259.
  • Chen J. F., Sonsalla P. K., Pedata F., Melani A., Domenici M. R., Popoli P., Geiger J., Lopes L. V. and De Mendonça A. (2007) Adenosine A2A receptors and brain injury. Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Progr. Neurobiol. 83, 310331.
  • Chevaleyre V., Takahashi K. A. and Castillo P. E. (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 3776.
  • Diana M. A. and Marty A. (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br. J. Pharmacol. 142, 919.
  • Doherty J. and Dingledine R. (2003) Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr. Opin. Pharmacol. 3, 4653.
  • Domenici M. R., Pepponi R., Martire A., Tebano M. T., Potenza R. L. and Popoli P. (2004) Permissive role of adenosien A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J. Neurochem. 90, 12761279.
  • Ferré S., Karcz –Kubicha M., Hope B. T. et al. (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl Acad. Sci. USA 99, 1194011945.
  • Ferré S., Agnati L. F., Ciruela F., Lluis C., Woods A. S., Fuxe K. and Franco R. (2007a) Neurotransmitter receptor heteromers and their integrative role in “local modules”: the striatal spine module. Brain Res. Rev. 55, 5567.
  • Ferré S., Ciruela F., Woods A. S., Lluis C. and Franco R. (2007b) Functional relevance of neurotransmitterreceptor heteromers in the central nervous system. Trends Neurosci. 30, 440446.
  • Ferré S., Ciruela F. and Quiroz C. (2007c) Adenosine receptor heteromers and their integrative role in striatal function. Sci. World J. 7, 7485.
  • Ferré S., Goldberg S. R., Lluis C. and Franco R. (2008) Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 56, 226234.
  • Fredholm B. B., Chern Y., Franco R. and Sitkovsky M. (2007) Aspects of the general biology of adenosine A2A signalling. Prog. Neurobiol. 83, 263276.
  • Freund T. F., Katona I. and Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signalling. Physiol. Rev. 83, 10171066.
  • Gerdeman G. L. and Lovinger D. M. (2001) Cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Physiol. 85, 468471.
  • Gerdeman G. L., Ronesi J. and Lovinger D. M. (2002) Postsynaptic endocannabinoid release is critical to long term depression in the striatum. Nat. Neurosci. 5, 446451.
  • Hampson A. J. and Grimaldi M. (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eu. J. Neurosci. 13, 15291536.
  • Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., De Costa B. R. and Rice K. C. (1990) Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 19321936.
  • Herkenham M., Lynn A. B., De Costa B. R. and Richfield E. K. (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267274.
  • Huang C. C., Lo S. W. and Hsu K. S. (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532, 731748.
  • Jung K. M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., Mackie K. and Piomelli D. (2005) Stimulation of endocannabinoid formation in brain slices cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 68, 11961202.
  • Kim S. H., Won S. J., Mao X. O., Jin K. and Greenberg D. A. (2006) Molecular mechanism of cannabinoid protection from neuronal excitotoxicity. Mol. Pharmacol. 69, 691696.
  • Köfalvi A., Rodrigues R. J., Ledent C., Mackie K., Vizi E. S., Cunha R. A. and Sperlagh B. (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 25, 28742884.
  • Lauckner J. E., Hille B. and Mackie K. (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl Acad. Sci. USA 102, 1914419149.
  • Ledent C., Vaugeois J. M. and Schiffmann S. N. (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptors. Nature 388, 674678.
  • Manabe T., Wyllie D. J., Perkel D. J. and Nicoll R. A. (1993) Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J. Neurophysiol. 70, 14511459.
  • Marcellino D., Carriba P., Malgorzata F. et al. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54, 815823.
  • Marsicano G., Goodenough S., Monory K. et al. (2003) CB1 cannabinoid receptors and on-demand defence against excitotoxicity. Science 302, 8488.
  • Matyas F., Yanovsky Y., MacKie K., Kelsch W., Misgeld U. and Freund T. F. (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137, 337361.
  • Navarro G., Carriba P., Candia J. et al. (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2 and adenosine A2A G-protein -coupled receptors by combining bimolecular complementation and bioluminescence energy transfer. Sci. World J. 8, 10881097.
  • Nishi A., Liu F., Matsuyama S., Hamada M., Higashi H., Nairn A. C. and Greengard P. (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signalling. Proc. Natl Acad. Sci. USA 100, 13221327.
  • Pazos M. R., Sagredo O. and Fernàndez-Ruiz J. (2008) The endocannabinoid system in Huntington’s disease. Curr. Pharm. Des. 14, 23172325.
  • Pintor A., Tebano M. T., Martire A. et al. (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51, 10041012.
  • Piomelli D. (2003) The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4, 873884.
  • Popoli P., Minghetti L., Tebano M. T., Domenici M. R. and Massotti M. (2004) Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights and shadows. Crit. Rev. Neurobiol. 16, 99106.
  • Popoli P., Blum D., Martire A., Ledent C., Ceruti S. and Abbracchio M. P. (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington’s disease. Prog. Neurobiol. 81, 331348.
  • Rodrigues R. J., Alfaro T. M., Rebola N., Oliveira C. R. and Cunha R. A. (2005) Colocalization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92, 433441.
  • Romero J., Lastres–Becker I., De Miguel R., Berrendero F., Ramos J. A. and Fernandez-Ruiz J. (2002) The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol. Ther. 95, 137152.
  • Sagredo O., Garcia-Arencibia M., De Lago E., Finetti S., Decio A. and Fernàndez-Ruiz J. (2007) Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36, 8291.
  • Schiffmann S. N., Fisone G., Moresco R., Cunha R. A. and Ferré S. (2007) Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 83, 277292.
  • Schulz P. E., Cook E. P. and Johnston D. (1994) Changes in paired-pulse facilitation suggest presinaptic involvement in long-term potentiation. J. Neurosci. 14, 53255337.
  • Soria G., Castané A., Berrendero F., Ledent C., Parmentier M., Maldonado R. and Valverde O. (2004) Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur. J. Neurosci. 20, 22032213.
  • Svenningson P., Le Moine C., Fisone G. and Fredholm B. B. (1999) Distribution biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355396.
  • Tebano M. T., Pintor A., Frank C., Domenici M. R., Martire A., Pepponi R., Potenza R. L., Grieco R. and Popoli P. (2005) Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. J. Neurosci. Res. 7, 100107.
  • Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M. and Watanabe M. (2007) Subcellular arrangement of molecules for 2-Arachidonoylgycerol-mediated retrograde signalling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 27, 36633676.
  • Van der Stelt M. and Di Marzo V. (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 7, 3750.
  • Van der Stelt M., Veldhhuis W. B., Maccarone M., Bar P. R., Nicolay K., Veldink G. A., Di Marzo V. and Vliegenthart J. F. (2002) Acute neuronal injury, excitotoxicity, and endocannabinoid system. Mol. Neurobiol. 26, 317346.
  • Wilson R. and Nicoll R. (2002) Endocannabinoid signalling in the brain. Science 296, 678682.
  • Yao L., McFarland K., Fan P., Jiang Z., Ueda T. and Diamond I. (2006) Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl Acad. Sci. USA 103, 78777882.
  • Zhuang S. Y., Bridges D., Grigorenko E., McCloud S., Boon A., Hampson R. E. and Deadwyler S. A. (2005) Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48, 10861096.